Cancer Letters
Volume 291, Issue 1 , Pages 120-129 , 1 May 2010

Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma

  • Elizabeth Brandon-Warner

      Affiliations

    • Department of Biology, The University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC 28223, USA
    • Department of General Surgery, Carolinas Medical Center, 1000 Blythe Blvd., Charlotte, NC 28203, USA
    • ,
  • James A. Sugg

      Affiliations

    • Department of Biology, The University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC 28223, USA
    • ,
  • Laura W. Schrum

      Affiliations

    • Department of Biology, The University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC 28223, USA
    • ,
  • Iain H. McKillop

      Affiliations

    • Department of General Surgery, Carolinas Medical Center, 1000 Blythe Blvd., Charlotte, NC 28203, USA
    • Corresponding Author InformationCorresponding author. Address: Department of General Surgery, Carolinas Medical Center, Cannon Research Building, Room 402, 1000 Blythe Blvd, Charlotte, NC 28203, USA. Tel.: +1 44 1 704 355 2846; fax: +1 44 1 704 355 7202.

Received 2 June 2009 ,Revised 5 October 2009 ,Accepted 8 October 2009.

References 

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  2. Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res. Health. 2007;30:38–41pp. 44–47
  3. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007;8:292–293
  4. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer. 2006;6:674–687
  5. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J. Surg. Res. 2006;136:125–135
  6. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol. Aspects Med. 2008;29:9–16
  7. McKillop IH, Schrum LW. Alcohol and liver cancer. Alcohol. 2005;35:195–203
  8. Jelski W, Zalewski B, Szmitkowski M. The activity of class I, II, III and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer. Dig. Dis. Sci. 2008;53:2550–2555
  9. Crabb DW, Liangpunsakul S. Acetaldehyde generating enzyme systems: roles of alcohol dehydrogenase, CYP2E1 and catalase, and speculations on the role of other enzymes and processes. Novartis Found. Symp. 2007;285:4–16(discussion pp. 16–22, 198–199)
  10. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol. Med. 2008;44:723–738
  11. Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Thier R, et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2 2A6 2E1 and 3A4 enzymes. Environ. Health Perspect. 1994;102(Suppl. 9):49–53
  12. Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival–death switch. J. Gastroenterol. Hepatol. 2006;21(Suppl. 3):S3–S6
  13. Lu SC, Mato JM. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J. Gastroenterol. Hepatol. 2008;23(Suppl. 1):S73–S77
  14. Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock. 2008;30:197–205
  15. Mato JM, Lu SC. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology. 2007;45:1306–1312
  16. Rambaldi A, Gluud C. S-adenosyl-l-methionine for alcoholic liver diseases. Cochrane Database Syst. Rev. 2006;CD002235
  17. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig. Dis. Sci. 2005;50:1807–1812
  18. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269:352–362
  19. Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15:9–20
  20. Jablonski EM, Mattocks MA, Sokolov E, Koniaris LG, Hughes FM, Fausto N, et al. Increased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett. 2007;250:36–46
  21. Kovach SJ, Sitzmann JV, McKillop IH. Inhibition of alcohol dehydrogenase blocks enhanced Gi-protein expression following ethanol treatment in experimental hepatocellular carcinoma in vitro. Eur. J. Gastroenterol. Hepatol. 2001;13:1209–1216
  22. Moran D, Koniaris LG, Jablonsi EM, Cahill PA, Halberstadt CR, McKillop IH. Microencapsulation of engineered cells to deliver sustained high circulating levels of interlukin-6 to study hepatocellular carcinoma progression. Cell Transplant. 2006;15:785–798
  23. Koop DR. Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a. Mol. Pharmacol. 1986;29:399–404
  24. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310
  25. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology. 1997;26:1484–1491
  26. Freeman TL, Tuma DJ, Thiele GM, Klassen LW, Worrall S, Niemela O, et al. Recent advances in alcohol-induced adduct formation. Alcohol. Clin. Exp. Res. 2005;29:1310–1316
  27. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekaninejad MS, Esmaeili R, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2 through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur. J. Pharmacol. 2008;591:13–20
  28. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J. Gastroenterol. 2007;13:5299–5305
  29. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin–phosphatidylcholine complex (Siliphos). Altern. Med. Rev. 2005;10:193–203
  30. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal. 2007;45:635–641
  31. Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front. Biosci. 2008;13:2191–2202
  32. Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res. 2005;11:8441–8448
  33. Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat. Res. 2004;555:21–32
  34. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. 2007;CD003620
  35. Gazak R, Walterova D, Kren V. Silybin and silymarin – new and emerging applications in medicine. Curr. Med. Chem. 2007;14:315–338
  36. Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem. Biol. Interact. 1994;91:51–63
  37. Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?. Alcohol Clin. Exp. Res. 2005;29:166S–171S
  38. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal, kinase, and apoptosis. J. Immunol. 1999;163:6800–6809
  39. Saliou C, Valacchi G, Rimbach G. Assessing bioflavonoids as regulators of NF-kappa B activity and inflammatory gene expression in mammalian cells. Methods Enzymol. 2001;335:380–387
  40. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin. Rev. Allergy Immunol. 2009;36:4–12
  41. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci. 2004;80:14–25
  42. Seidlova-Wuttke D, Becker T, Christoffel V, Jarry H, Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J. Steroid. Biochem. Mol. Biol. 2003;86:179–188
  43. Kovacs EJ, Messingham KA. Influence of alcohol and gender on immune response. Alcohol Res. Health. 2002;26:257–263
  44. Ronis MJ, Wands JR, Badger TM, de la Monte SM, Lang CH, Calissendorff J. Alcohol-induced disruption of endocrine signaling. Alcohol. Clin. Exp. Res. 2007;31:1269–1285
  45. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008;68:2043–2050

PII: S0304-3835(09)00626-0

doi: 10.1016/j.canlet.2009.10.004

Cancer Letters
Volume 291, Issue 1 , Pages 120-129 , 1 May 2010

Article Tools

* Image Usage & Resolution